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The progesterone derivative allopregnanolone (ALLO) is one of the most widely
studied compounds among neurosteroids. Through interactions with GABA-A receptors
expressed by neurons and glial cells, ALLO has been shown to affect diverse aspects
of neural cell physiology, including cell proliferation and survival, migration, and gene
expression. Recent data point to important roles for ALLO in different neurodegenerative
disorders, including Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS).
Dysregulation in ALLO biosynthesis pathways has been reported in brain tissue from
MS patients as well as in the central nervous system (CNS) tissue derived from MS
animal models. Administration of ALLO has been shown to ameliorate neurobehavioral
deficits together with neuropathology and inflammation in the CNS of animals with
autoimmune demyelination. These findings are in line with previous reports indicating
growth- and differentiation-promoting actions of ALLO on neurons and glial cells as well
as its neuroprotective effects in the context of other CNS diseases. Nonetheless, these
findings have also raised the possibility that ALLO might influence leukocyte biology
and associated neuroinflammatory mechanisms independent of its neuroregenerative
properties. Herein, we review the current knowledge regarding the role of ALLO in the
pathogenesis of MS, and discuss the potential cellular and molecular pathways that might
be influenced by ALLO in the context of disease.
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INTRODUCTION
Steroids synthesized from precursors in central or peripheral ner-
vous systems have attracted substantial attention in recent years
(Mellon and Griffin, 2002; Brinton, 2013). While the blood-brain
barrier (BBB) is permissive to steroids produced by gonads and
adrenals, the precise neuroanatomical segregation of the locally-
synthesized steroids, i.e., neurosteroids, gives them a distinct
advantage over peripheral steroids in terms of exerting region-
specific effects in the nervous system. In addition to binding to
intracellular steroid receptors, some neurosteroids interact with
neurotransmitter receptors, thus influencing the biology of select
types of neural cells (Belelli and Lambert, 2005). Reduction of
locally-synthesized or peripherally-derived progesterone to dehy-
droprogesterone (DHP) and tetrahydroprogesterone (THP) is
one of the widely studied arms of the neurosteroid synthesis path-
way. While progesterone and DHP can both bind to intracellular
steroid receptors, the predominant THP form, allopregnanolone,
can only interact with and signal through cell surface GABA-A
receptors.
Multiple sclerosis (MS) is a complex disease of the CNS
with both inflammatory and degenerative aspects (Sospedra and
Martin, 2005; Trapp and Nave, 2008). Neuropathologically, MS
is characterized by leukocyte infiltration of CNS followed by
myelin damage, local gliosis, and axonal injury. It is generally
believed that the pathogenic process of MS is initiated by a break-
down of immune tolerance to CNS antigens due to genetic or
environmental factors, leading to activation and proliferation of
neuroantigen-reactive T cells in the peripheral immune system
in susceptible individuals (Hemmer et al., 2002). Activated T cells
and macrophages then infiltrate the CNS and become reactivated,
leading to local microglial activation and intraparenchymal gen-
eration of chemokines and inflammatory cytokines. Subsequent
waves of lymphocytic and monocytic cell infiltration into the
CNS give rise to widespread neuroinflammation with ensuing
myelin damage and axonal injury (Sospedra and Martin, 2005).
Some evidence gives more weight to innate immune events,
compared with adaptive immune processes, in MS neuroinflam-
mation (Tsutsui et al., 2005; Mayo et al., 2012). An alternative
view holds that initial neurodegenerative events, including apop-
tosis of oligodendrocytes or structural alteration of myelin, might
occur in early stages of disease and then trigger subsequent
inflammatory phenomena (Moscarello et al., 2007; Prineas and
Parratt, 2012; Stys et al., 2012). Regardless of whether the ini-
tiating event in the MS disease process is an innate or adaptive
immune dysregulation or a neurodegenerative/cell death phe-
nomenon, destruction of myelin and axonal damage are the final
pathogenic outcomes which underlie signs and symptoms of the
disease.
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The localized and well-demarcated nature of pathology in MS
begs the question of whether a focal dysregulation in the CNS
microenvironment might contribute to the disease process in
addition to the infiltration of myelin-reactive T cells and other
leukocytes. Numerous studies have shown the link between MS
with steroid hormones (El-Etr et al., 2005; Simpkins et al., 2005;
Kipp and Beyer, 2009). Following the discovery of neurosteroids
in the CNS, efforts were made to elucidate the role of these com-
pounds and their potential dysregulation in the context of MS
and neuroinflammation. Herein, we review the current knowl-
edge regarding the role of ALLO in the MS disease process. The
first part of this review concentrates on the effects of ALLO on
major cellular players in MS pathogenesis, i.e., oligodendrocytes,
monocytoid cells, and lymphocytes. While direct effects of ALLO
on neuronal physiology might also be important in the context of
MS and in particular on the degree of axonal injury which is cor-
related with MS symptoms, we have not included the neuronal
effects of ALLO here and we refer the interested reader to other
reviews on this subject (Charalampopoulos et al., 2006, 2008;
Leskiewicz et al., 2006). In the second part of the review, we assess
the evidence supporting the involvement of ALLO in MS patho-
genesis, including studies in animal models of disease, as well as
its potential for therapeutic interventions.
ALLO AND MS PATHOGENESIS; CELLULAR PLAYERS
ALLO, OLIGODENDROCYTES, AND MYELINATION
The effects of progesterone and its derivatives in promot-
ing myelin formation in the peripheral nervous system (PNS)
have been recognized for almost two decades (Baulieu and
Schumacher, 1997). Schwann cells have been shown to express
functional GABA-A receptors and respond to ALLO treatment
by upregulating two major myelin proteins, i.e., myelin pro-
tein 22 and P0 (Melcangi et al., 1999). Progesterone and ALLO
were later reported to induce myelin basic protein (MBP) gene
expression in brain organotypic slice cultures (Ghoumari et al.,
2003). While the effect of progesterone on MBP gene expression
was shown to be largely mediated by intracellular progesterone
receptors, effects of ALLO were mediated by GABA-A recep-
tors expressed on oligodendrocytes (Ghoumari et al., 2003). In
addition to promoting myelin protein gene expression in mature
oligodendrocytes, progesterone has been illustrated to enhance
the proliferation of oligodendrocyte precursors in cerebellar slice
cultures through intracellular progesterone receptors, but a sim-
ilar effect has not been reported for ALLO (Ghoumari et al.,
2005). That said, ALLO has been shown to induce proliferation of
rat hippocampal neuroprogenitor cells or human cortical neural
stem cells, with the resulting cells showing neuronal phenotype
(Wang et al., 2005). In addition to its promyelinating effects,
ALLO has been reported to protect oligodendrocytes against cyto-
toxic stimuli. When treated with recombinant TNF-α, cultured
rat oligodendrocytes display reduced viability as quantified by
CNPase immunoreactivity. Pretreatment with ALLO (100 nM)
reduced the toxicity of TNF-α (Noorbakhsh et al., 2011). Overall,
it seems that ALLO exerts promyelinating as well as cytopro-
tective effects on oligodendrocytes against inflammatory stimuli,
and both effects are relevant because of the beneficial outcomes
in the context of autoimmune demyelination.
ALLO AND MONOCYTOID CELLS
Macrophages are known to express functional GABA-A receptors,
and the activation of the receptors leads to reduced production
of inflammatory cytokines by these cells (Reyes-Garcia et al.,
2007). Treatment with different GABA-A agonists have been
shown to alter the behavior of macrophages and dendritic cells
and the resulting T cell response following antigen presentation
(Bhat et al., 2010). When treated with ALLO, murine peritoneal
macrophages have been demonstrated to produce lower levels of
TNFα after LPS stimulation (Ghezzi et al., 2000). In a study from
our group, treatment of human monocyte-derived macrophages
with ALLO (100 nM) reduced the production of IL-1β and TNF-
α transcripts after PMA exposure. ALLO treatment also reduced
macrophage expression of IDO, an enzyme involved in a variety
of inflammatory processes (Noorbakhsh et al., 2011).
In addition to monocyte infiltration of the CNS, activation of
microglia, the resident monocytoid cells of the brain, also plays
an critical role during neuroinflammatory processes (Jack et al.,
2005). Similar to macrophages, microglia have been illustrated
to express both GABA-A and GABA-B receptors, and treatment
with the GABA-A agonist muscimol reduces microglial produc-
tion of inflammatory mediators following LPS stimulation (Lee
et al., 2011). Nonetheless, studies investigating the effect of ALLO
on microglial function are limited. A study by Muller et al. has
shown decreased production of NO by LPS-stimulated microglial
BV2 cell lines after treatment with either progesterone or ALLO
(Muller and Kerschbaum, 2006). While still an underappreciated
area, the consequences of microglial GABA-A signaling might
not be limited to reduced proinflammatory activity of these cells.
An interesting study by Mead et al. has shown that activation
of GABA-A receptors on microglia can lead to enhanced activ-
ity of different isoforms of NADPH oxidase (Nox), the enzyme
responsible for generation of superoxide ions (Mead et al., 2012).
While Nox activation by glutamate signaling leads to a neuro-
toxic phenotype, GABA-A-receptor-mediated activation of the
enzyme promotes a neuroprotective phenotype (Mead et al.,
2012). It remains to be explored if ALLO-mediated activation
of microglial GABA-A receptors might contribute to differen-
tiation of the cells toward a neuroprotective anti-inflammatory
phenotype.
ALLO AND LYMPHOCYTES
While altered activity of antigen presenting cells after exposure
to ALLO or other GABA-A receptor agonists could translate
into alterations in lymphocyte proliferation and differentiation,
little is known about direct effects of ALLO on lymphocytes.
Human and murine lymphocytes have been shown to express
functional GABA-A receptors (Mendu et al., 2012). Treatment
with the GABA-A agonist muscimol have been shown to inhibit
antigen-specific T cell proliferation (Tian et al., 1999) and GABA-
A activation leads to whole-cell transient and tonic currents in
T lymphocytes (Mendu et al., 2012). Nonetheless, in a study
by our group, ALLO treatment of splenocyte cultures derived
from animals immunized with a myelin antigen did not affect
cell proliferation after antigenic re-stimulation (Noorbakhsh
et al., 2011). Moreover, ALLO treatment did not affect differ-
entiation of antigen-stimulated lymphocytes to Th1 or Th17
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pathogenic phenotypes, as measured by intracellular immunos-
taining of IFN-γ and IL-17, the prototypic Th1/Th17 cytokines
(Noorbakhsh et al., 2011). While these findings do not rule out
the possibility of ALLO acting directly on lymphocytes, they are
more supportive of the role of ALLO as a modulator of innate
immune function.
ALLO AND LEUKOCYTE MIGRATION THROUGH BLOOD BRAIN BARRIER
(BBB)
A critical step in the process of autoimmune neuroinflammation
is the traversing of the BBB by peripherally-activated leuko-
cytes. These cells include neuroantigen-reactive lymphocytes or
monocytes entering the CNS following the chemokine gradient
generated by locally activated microglia or previously infiltrated
lymphocytes. Both progesterone and ALLO have been demon-
strated to reduce BBB dysfunction following focal ischemia
(Ishrat et al., 2010). This effect has been partly attributed to
suppressed expression of MMP-2 and MMP-9 in ischemic brain
following ALLO treatment (Ishrat et al., 2010). Moreover, ALLO
was shown to prevent degradation of the BBB tight junction
proteins occludin 1 and claudin 5 (Ishrat et al., 2010). While
it remains to be investigated, it is conceivable that ALLO treat-
ment could also affect BBB permeability and leukocyte trafficking
during autoimmune inflammation.
We have summarized the effects of ALLO on different cellular
elements with known roles in MS pathogenesis (Figure 1).
ALLO AND MS PATHOGENESIS, HUMAN STUDIES AND
ANIMAL MODELS
The role of progesterone and its potential derivatives in demyeli-
nating diseases has been studied for many years (Shuster, 2008).
Before the identification of neurosteroid synthesis pathways in
the brain, it had been reported that treatment of mice with
experimental autoimmune encephalomyelitis (EAE) with pro-
gestins ameliorated disease severity (Arnason and Richman,
1969a,b). Later studies further highlighted the protective and
anti-inflammatory role of progesterone in EAE (Garay et al.,
2007). Progesterone treatment of neuroantigen-reactive CD4+ T
cells isolated fromMS patients was shown to affect their cytokine
production (Correale et al., 1998). Progesterone and its reduced
form dehydroprogesterone (DHP) can bind to intracellular pro-
gesterone receptors and exert genomic effects via altered expres-
sion of progesterone-responsive genes. However, ALLO lacks this
ability and can only exert its effects through interactions with
GABA-A receptors (Paul and Purdy, 1992). Considering that
exogenously-administered progesterone could be readily reduced
to ALLO in different cells, the protective effects reported for
progesterone have likely been the consequence of both genomic
regulation and GABA-A receptor-mediated pathways.
Subsequent studies provided more specific evidence support-
ing the role of ALLO inMS pathogenesis. In a study performed on
human autopsy brain tissues, our group showed that ALLO levels
were significantly reduced in the brain white matter derived from
FIGURE 1 | ALLO exerts various effects on cells involved in MS
pathogenesis. Functional GABA-A receptors are expressed by neurons,
oligodendrocytes, monocytoid cells, and lymphocytes. ALLO promotes
myelin gene expression by oligodendrocytes and protects them against
injurious stimuli. Neuroprotective effects have also been reported for
neurons. ALLO’s binding to GABA-A receptors on monocytoid cells leads to
diminished production of inflammatory mediators by these cells. These
effects, together with diminished BBB permeability and potential influence
on lymphocytes, contribute to the beneficial roles of ALLO in the context of
autoimmune demyelination.
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MS patients compared with control individuals (Noorbakhsh
et al., 2011). The reduction was associated with diminished levels
of two crucial upstream enzymes which are involved in conversion
of progesterone to ALLO, i.e., 5-α-reductase and AKR1C1/C2,
in brain white matter of MS patients. The levels of the further
upstream enzyme, 3-α-HSD, which is involved in conversion of
pregnenolone to progesterone, was not altered in MS brains.
Interestingly, analysis of the levels of 3α,5β-THP, a minor isoform
of THP, did not show any changes in the same brain tissues, indi-
cating a specific downregulation in 3α,5α-ALLO isoform. Similar
analysis of spinal cord tissues derived from EAE mice showed
decreased levels of ALLO, but not the minor THP isoforms in
EAE mice compared with control animals (Noorbakhsh et al.,
2011). Again, ALLO suppression was associated with diminished
RNA and protein levels of murine isoforms of the AKR1 enzymes,
akr1c14, and akr1e1. Treatment of EAE mice with daily intraperi-
toneal injections of ALLO, which were started after the onset of
neurological signs, reduced disease severity. Neuropathological
analyses of the spinal cords from the same animals revealed
diminished myelin damage and axonal injury in ALLO-treated
animals, a finding that was consistent with the clinical features.
These observations were also associated with lower levels of lym-
phocyte infiltration and monocyte/microglial activation in the
CNS (Noorbakhsh et al., 2011).
Enhanced synthesis of endogenous ALLO has also been
reported to be protective in the context of autoimmune demyeli-
nation. Translocator protein (TSPO) is a transfer protein located
in the outer membrane of mitochondria (Papadopoulos et al.,
2006; Gatliff and Campanella, 2012) previously termed the
peripheral benzodiazepine receptor and a recognized marker for
activated glial cells (Venneti et al., 2006). Through interactions
with StAR (steroidogenic acute regulatory protein), TSPO exerts
a rate-limiting step in the transfer of cholesterol into mitochon-
dria, where it can be converted to pregnenolone (Rone et al.,
2009). It has been shown that modulation of TSPO activity with
etifoxine, a TSPO ligand, can enhance neurosteroid synthesis in
brain (Girard et al., 2012; Nothdurfter et al., 2012). A recent
study has shown that modulation of TSPO activity with etifox-
ine ameliorates disease symptoms and neuropathology in mice
affected with EAE (Daugherty et al., 2013). The treatment was
effective when the drug was administered at the presymptomatic
stage of disease or at the peak of disease. The protective effect
of TSPO activation was shown to be associated with specific
upregulation of the murine enzyme responsible for ALLO syn-
thesis, i.e., akr1c14 (Daugherty et al., 2013). Other TSPO ligands
have also been reported to diminish microglial activation, an
effect that is likely mediated through enhanced microglial neu-
rosteroid synthesis (Zhao et al., 2011; Leaver et al., 2012). Of note,
TSPO shows upregulation on astrocytes and microglia in a vari-
ety of neuroinflammatory disorders, which might be a part of
an endogenously-regulated protective response in the context of
neuroinflammation (Abourbeh et al., 2012; Lavisse et al., 2012).
FUTURE PERSPECTIVES: ALLO AS A THERAPY FOR MS
Since the discovery of ALLO dysregulation in several neuro-
logical disorders, ALLO and its synthetic analogs have been
considered for their potential therapeutic or disease modifying
effects in brain disease (Brinton, 2013). Currently, the majority
of evidence supporting a beneficial role for ALLO and its analogs
comes from animal models, with few studies having tested the
effects of ALLO treatment on humans. In a pioneering study by
Griffin et al., ALLO was shown to diminish neurological signs
and neuropathology in a mouse model of Niemann-Pick disease
(Griffin et al., 2004). ALLO treatment was later shown to decrease
beta-amyloid burden and memory deficits in triple-transgenic
mouse models of Alzheimer’s disease (Wang et al., 2010; Singh
et al., 2012), restore dopaminergic neurons and motor perfor-
mance in the MPTP model of Parkinson’s disease (Adeosun et al.,
2012), exert anticonvulsant activity and decrease neuronal injury
in models of epilepsy (Mares et al., 2006, 2010; Singh et al.,
2010), reduce infarct volume and improve cognitive outcome
in models of brain ischemia (Sayeed et al., 2006; Morali et al.,
2011), and reduce neuronal death and gliosis after traumatic
brain injury (TBI) (Djebaili et al., 2005). Of note, the protective
effects of ALLO in TBI have been clearly linked with its anti-
inflammatory functions (He et al., 2004; VanLandingham et al.,
2007). Evidence for potential therapeutic roles for ALLO in MS
also comes from animal studies showing reduced neuroinflam-
mation and disease burden in the EAE animal model of disease
after treatment with ALLO or TSO ligands, which lead to induc-
tion of ALLO-synthesizing enzymes (Noorbakhsh et al., 2011;
Daugherty et al., 2013). While several reports have demonstrated
the safety of ALLO administration to humans (Timby et al., 2006;
van Broekhoven et al., 2007), ALLO trials on human disease are
limited, in part because of costs and the quantity of drug needed
for therapeutic purposes. Of interest, ganaxolone, an ALLO syn-
thetic analog, has been successfully used to control epilepsy in
human cases (Nohria and Giller, 2007; Pieribone et al., 2007), and
recent studies from our group indicate that ganaxolone also exerts
anti-inflammatory effects in EAE (Paul et al., 2014). Clinical trials
to evaluate the therapeutic effects of ALLO in TBI are currently
underway (Clinicaltrials.gov, NCT01673828), while ALLO trials
for treating mild cognitive impairment and Alzheimer’s disease
are also expected (Irwin and Brinton, 2014). Overall, considering
the wealth of knowledge derived from in vitro and in vivo analyses,
together with low toxicity and good tolerance in human subjects,
ALLO and its analogs are excellent candidates waiting to be tested
in MS and other neuroinflammatory disorders.
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